Balchem (BCPC) Q1 2026 earnings summary

Executive summary

• Achieved record first quarter consolidated sales of $270.7 million, up 8.1% year-over-year, with growth and strong cash flow across all business segments.

• Net earnings rose 8.7% to $40.3 million, and adjusted EBITDA increased 12.1% to $74.3 million, reflecting sustained operational momentum.

• Strategic growth initiatives, acquisitions, and sustainability efforts advanced, including the release of the 2025 Sustainability Report and new clinical research on VitaCholine.

• All three segments—Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products—delivered solid top and bottom line growth.

• Demonstrated resilience and adaptability amid evolving global market and geopolitical conditions.

Financial highlights

• Quarterly consolidated revenue reached $270.7 million, up 8.1% year-over-year, with gross margin dollars up 14.6% to $101.1 million and margin percent expanding to 37.3%.

• Adjusted EBITDA was $74.3 million, up 12.1%, with a margin of 27.4%; net income was $40.3 million, up 8.7%, and adjusted net earnings were $43 million, or $1.33 per diluted share, up 9%.

• Cash flows from operations were $40.1 million, with free cash flow of $33.8 million and $72.9 million in cash at quarter-end.

• Operating expenses increased, mainly due to higher compensation and professional services.

• Repurchases of common stock totaled $15.7 million and dividend payments were $30.8 million in Q1 2026.

Outlook and guidance

• Expectation of continued quarterly year-over-year consolidated growth, supported by strategic initiatives, innovation, and market expansion, despite modest margin compression from input cost inflation and pricing lag.

• Management remains confident in delivering top and bottom line growth for the remainder of 2026 and beyond.

• Effective tax rate for planning remains at 23%, with some quarterly fluctuations expected.

• Management expects sufficient cash flow to fund working capital and capital investments, and is actively pursuing additional acquisitions.

• No material impact expected from recent Supreme Court tariff ruling or new tariffs; monitoring ongoing developments.